2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Thalassemia, Immunology, Autoimmune Hemolytic Anemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1120 Favorable response to second-line sirolimus regardless of STAT3/5b status in acquired pure red cell aplasia: A retrospective study from a single center

Zexing Sun, Xinru Jia2, Yingying Shen3, Xiawan Yang4, Qi Liu5, Hangping Ge Jr6, Yun Zhang II, MMed7, Zhiyin Zheng8, Yiping Shen9, Yuhong Zhou10, Dijiong Wu, MD,PhD11
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
9 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
10 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
11 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Acquired pure red cell aplasia (PRCA) is a rare hematologic syndrome characterized by severe normocytic normochromic anemia, reticulocytopenia, and a selective absence of erythroid precursors in the bone marrow. Given its autoimmune nature, immunosuppressive therapy, particularly cyclosporine A (CsA), is widely accepted as the standard first-line treatment. However, treatment outcomes are heterogeneous, and a subset of patients fails to respond to initial CsA therapy or experiences relapse during maintenance therapy. This issue of treatment failure is particularly pronounced in secondary PRCA, which is frequently associated with conditions such as T-cell large granular lymphocyte leukemia (T-LGLL). While sirolimus has emerged as a potential alternative salvage therapy for patients failing first-line CsA, data on its use remain limited to small case series. Furthermore, although STAT3 and STAT5b mutations are recognized pathogenic drivers in acquired PRCA, their clinical utility in guiding treatment selection between CsA and sirolimus remains unclear. Herein, we conducted a retrospective, single-center study to evaluate the efficacy of first-line CsA in primary versus secondary PRCA, assess the feasibility and efficacy of second-line sirolimus for patients with CsA failure or intolerance, and explore the association between STAT3/5b mutation status and treatment response.

A total of 36 patients with acquired PRCA who received first-line CsA between September 2021 and September 2025 at the Department of Hematology, Zhejiang Chinese Medical University Hospital, were consecutively enrolled in this study. Among these, 22 patients subsequently transitioned to sirolimus salvage therapy due to a lack of response or intolerance to CsA. Comprehensive demographic and clinical characteristics of the cohort were documented (Table 1). The overall response rate (ORR) for first-line CsA was 25.0%, and the ORR for the salvage sirolimus group was 54.5% (Figure 2). Regarding genetic predictors on efficacy, no responses to CsA were observed in patients harboring STAT3/5b mutations (0/6) (Figure 3A). In contrast, sirolimus elicited responses in both mutated (50.0%, 3/6) and wild-type (80.0%, 4/5) patients, indicating therapeutic efficacy irrespective of STAT3/5b status (Figure 3B). When evaluating treatment outcomes in primary versus secondary PRCA, significantly higher efficacy of first-line CsA was observed in primary cases (42.1%) than in secondary cases (5.9%) (Figure 4A). In the salvage sirolimus group, substantial efficacy was demonstrated in both primary (37.5%) and secondary cases (64.3%) (Figure 4B). The median time to response (TTR) did not differ significantly between sirolimus and CsA (3.0 vs. 1.5 months), and both agents achieved sustained remission in responders without documented relapses during the observation period (Figure 5). Regarding adverse events, documented complications in the CsA group mainly included hepatic or renal impairment (13.9%), whereas infectious complications, particularly pneumonia (31.8%), were the predominant adverse events in the sirolimus salvage group.

In summary, CsA is an effective first-line treatment for primary PRCA, whereas sirolimus demonstrates substantial efficacy as a salvage therapy in both primary and secondary cases, regardless of STAT3/5b mutation status. Early genetic profiling of STAT3/5b may facilitate the identification of patients who may not fully respond to CsA, potentially guiding an earlier transition to sirolimus salvage therapy for long-term disease control.

Dijiong Wu, MD,PhD: No relevant conflicts of interest to declare.